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Abstract 
Drugs have become an essential part of our lives due to their ability to improve people’s 
health and quality of life. However, for many diseases, approved drugs are not yet available 
or existing drugs have undesirable side effects, making the pharmaceutical industry strive to 
discover new drugs and active compounds. The development of drugs is an expensive 
process, which typically starts with the detection of candidate molecules (screening) for an 
identified protein target. To this end, the use of high-performance screening techniques has 
become a critical issue in order to palliate the high costs. Therefore, the popularity of 
computer-based screening (often called virtual screening or in-silico screening) has rapidly 
increased during the last decade. A wide variety of Machine Learning (ML) techniques has 
been used in conjunction with chemical structure and physicochemical properties for 
screening purposes including (i) simple classifiers, (ii) ensemble methods, and more recently 
(iii) Multiple Classifier Systems (MCS). In this work, we apply an MCS for virtual screening 
(D2-MCS) using circular fingerprints. We applied our technique to a dataset of cannabinoid 
CB2 ligands obtained from the ChEMBL database. The HTS collection of Enamine 
(1.834.362 compounds), was virtually screened to identify 48.432 potential active molecules 
using D2-MCS. This list was subsequently clustered based on circular fingerprints and from 
each cluster, the most active compound was maintained. From these, the top 60 were kept, 
and 21 novel compounds were purchased. Experimental validation confirmed six highly 
active hits (>50% displacement at 10 µM and subsequent Ki determination) and an 
additional five medium active hits (>25% displacement at 10 µM). D2-MCS hence provided a 
hit rate of 29% for highly active compounds and an overall hit rate of 52%.  
Keywords 
Drugs discovery, clustering methods, measure-guided methodology, ensembling schemes  
Introduction 
In silico (or computational drug discovery) relies on different computer-based techniques to 
find a novel or improved bioactive compound, which should exhibit a strong affinity to a 
particular target. Although in-silico screening is present in the drug development process 
since the beginning of 90s [1, 2] its relevance has been progressively increasing until 
becoming an essential part of the drug-development process. This fact was mainly motivated 
by (i) a significant improvement in the performance of computer systems, (ii) the introduction 
of novel algorithms and more expressive molecular descriptors, and (iii) the advent of large-
scale public bioactivity databases [3].  
Limited processing capabilities of computer systems during the 90s led to in silico screening 
mainly focused on (i) building simple mathematical modelling approaches (often 
implemented as cellular automatons) for large-scale simulations of complex systems [4], (ii) 
the development of big-data databases enables researchers to easily store and access the 
information [2] or (iii) the design of affinity fingerprints as novel descriptors for similarity 
searches in molecular databases and QSAR analyses [5]. As computers’ performance 
increased, the use of simple Machine Learning (ML) classification schemes for screening 
purposes became popular. Concretely, the usage of Support Vector Machines (SVM) [6, 7], 
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Decision Trees (DT) [8], Naïve Bayes [9], K-Nearest Neighbourhoods (KNN) [10], Artificial 
Neural Networks [11] and Self Organizing Maps (SOM) [12] were widely applied in the 
domain. 
However, during the last decade, the amount of public information available for screening 
has increased rapidly with the introduction of resources such as ChEMBL and PubChem [3, 
13]. This fact had a negative impact on the performance of simple ML approaches due to 
their trend to build unstable classification models when handling a high volume of 
information. In order to improve this situation and therefore, increase the predictive 
performance, ML models were equipped with multiple layers (stacking, deep learning) and 
identical ML algorithms were combined (ensemble of classifiers [14]). Specifically, in [15] 
authors demonstrate the suitability of using of Deep Neural Networks (DNN) [16] and 
Random Forests (RF) [17] methods against single ML models (such as Naïve Bayes or 
SVM) to predict the bioactivity of molecules. Additionally, latest research work [18, 19] 
applies several Boosting (such as AdaBoost or MultiBoost) and Fuzzy Forest approaches to 
predict (i) bioactivity of molecules and (ii) toxicity of non-congeneric industrial chemicals, 
respectively. 
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The usage of above-mentioned ensemble methods contributed to significant performance 
improvements in the virtual screening domain. However, their introduction also brought 
some important shortcomings such as: (i) the random selection of the information often used 
to build each inner classifier, (ii) the common usage of weak classifiers such as C4.5 or 
Decision Stumps to build up the classifier ensemble (although any ML classifier can be 
used) and, (iii) the impossibility combining different inner classifiers and configurations for 
them with concrete subsets of training information. These limitations are implicit to the 
definition of ensemble classifiers and are the key features to distinguish them against the 
great number of methods included in the Multiple Classifier Systems (MCS) [20] group. 
Wozniak et al. [20] revealed interesting features of MCS, including (i) their good performance 
when working in extreme situations such as scarcity of samples or information overload, (ii) 
their ability to outperform inner individual classifiers, (iii) the increase of the probability of 
finding an optimal model, and (iv) the reduction of the information (and hence the increase in 
the performance and speed) used to build each inner classifier. Keeping into account the 
above-mentioned issues we apply an MCS toolkit (called D2-MCS [21]) to increase the 
performance of virtual screening.  
Methods 
This section evaluates the suitability of using MCS and its application in drug discovery 
domain. It also introduces the dataset and measures used to perform the experimental 
protocol. Finally, the methodology performed to carry out the virtual screening process is 
explained in detail. 
Datasets 
CB2 dataset 
The data was gathered from ChEMBL version 22 based on UniProt accession P34972 [22]. 
The activity data were filtered for potential duplicates, no activity or data validity comments 
were allowed, and only data from binding assays with a pChEMBL value was kept. This led 
to 3,925 compounds. Subsequently, compound fingerprints (FCFP_6) and physicochemical 
properties were calculated (see supporting information in Additional File 1) [23]. The 
FCFP_6 fingerprints were computed using the fingerprints to properties component from 
Pipeline Pilot Version 2016.1.0 [24]; 2048 substructures/bits were selected based on their 
occurrence frequency in the data set [24]. A presence of 50% was the optimum frequency. 
Thereby, significant under- and overrepresentation were both avoided. Finally, the set was 
made into a binary classification set where the activity cut-off was set at a pChEMBL value > 
7 for active compounds and written to a tab-delimited text file using the InChiKey as unique 
identifier [25]. The final set contained 1,977 active compounds and 1,948 inactive 
compounds (CB2Set, supporting information [26]). The obtained dataset include 2,133 
attributes (84 physicochemical properties, 2,048 chemical-structure features and the activity 
class) to describe 3,925 compounds (instances). Table 1 shows the codification of each 
feature grouped by type. 
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 Table 1. Feature characteristics and codification 
Feature type Feature values Nº of features 
Chemical substructure fingerprints Binary  2,048 
Physicochemical descriptors 
Discrete Values 50 
Continuous Values  34 
Total 2,132 
As can be observed from Table 1 each chemical substructure is codified using a binary 
representation to indicate its presence (1) or absence (0) for each chemical compound. 
Additionally, the physicochemical descriptors consist of continuous or discrete values 
depending on the descriptor type and metric representation. 
Validation dataset 
The high-throughput screening (HTS) set was downloaded from the Enamine website 
(containing 1,834,362 compounds without class information). Molecules were standardized 
and encoded using the same feature representation as was used for the CB2 dataset (2048 
chemical substructure fingerprints and 84 physicochemical descriptors). This set will be 
referred to as ValidationSet.  
Evaluation measures 
Quite a few performance measures for assessing the accuracy and rank of different 
classification approaches exist in the drug discovery domain. Concretely, we select 
Matthews Correlation Coefficient (MCC) [27, 28] and Positive Predictive Values (PPV) [29–
31] measures due to their demonstrated ability to minimize false negatives (FN) and false 
positives (FP) errors respectively.  
MCC is a performance measure designed for binary classifiers that can be used in the case 
of imbalanced datasets (the distribution of instances in the classes is uneven). MCC can be 
easily computed from the values of the confusion matrix results (true positives or TP, true 
negatives or TN, false positives or FP and false negatives or FN) by using Equation 1. 
       
TP TN FP FN
MCC
TP FP FN TN FP TN TP FN
  

      
  1 
MCC is defined in the interval [-1,1], where 1 stand for no classification errors, -1 means that 
all input instances were misclassified and 0 reveals that the classification was absolutely 
uncorrelated with the real truth. As can be extrapolated from Equation 1, achieving a 
balanced number of positive and negative classification hits is mandatory to obtain higher 
MCC values. Additionally, the inclusion of the four quantiles (TP, TN, FP and FN) in the 
MCC formula allows giving a better summary of the performance of classification algorithms 
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regarding other well-known metrics (such as Accuracy [32] or F1-Score [33]). The benefits of 
using MCC against other well-known measures commonly used to evaluate ML approaches 
in the health domain has been demonstrated by Chicco [34]. 
From another perspective, PPV is a well-known measure in the drug discovery domain due 
to its ability to assess the probability of having a positive outcome given a positive result 
(also called a posteriori probability). Thus, PPV is an interesting measure since testing an 
inactive molecule (due to an FP error) is very expensive. Due to this, some previous works 
take advantage of it [35]. PPV can be computed by combining the values included in the 
confusion matrix in the form defined by Equation 2. 
TP
PPV
TP FP


  
2 
As could be noted, PPV is not able to accurately handle most situations if used in isolation. 
In fact, a classifier could reach the maximum PPV score by identifying only one active 
molecule. With regard to this, over a balanced dataset where the probability of finding one 
active molecule is ½, a classifier could randomly select one instance to classify it as active 
and assign the inactive label to the remaining ones. This classifier could achieve a PPV 
score of one in half of the experimentations (those which the instance classified as active 
was really active). Therefore, PPV needs to be accompanied by other performance 
indicators, such as MCC. 
Modelling 
To build our classification software we use D2-MCS due to its ability to easily build high-
performance in silico screening MCS models [21]. D2-MCS is an R-based toolkit that 
provides an efficient and flexible MCS mechanism that can be highly customized to ensure 
an adequate adaptation to the intrinsic characteristics of the target dataset. Particularly, D2-
MCS is able to handle high dimensional datasets by grouping the features of molecules 
(dataset columns) into several groups (called feature-clusters) according to user-defined 
criteria (i.e. type of chemical compounds, molecular weight, etc.). Then, for each feature-
cluster, the toolkit is able to automatically determine the most suitable classifier (simple or 
ensemble) together with its best configuration. According to this information, D2-MCS builds 
a set of classifiers (one per feature cluster) whose outputs will be combined to generate a 
single solution. The set of selected trained classifiers (one for each dataset part) together 
with a voting system comprises a whole D2-MCS instance. Figure 1 shows a global overview 
of the D2-MCS operation. 
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Figure 1. Structure and functionality of D2-MCS toolkit. D2-MCS builds a set of classifiers 
(one per feature cluster) whose outputs will be combined to generate a single solution. The 
set of selected trained classifiers (one for each dataset part) together with a voting system 
comprises a whole D2-MCS instance. 
As shown in Figure 1, D2-MCS operation is divided into three different stages. The first 
stage (called PREPROCESSING in Figure 1) comprises the partitioning of training 
information based on a specific feature-clustering algorithm. Although D2-MCS provides by 
default several clustering methods (Fisher, Information Gain, etc.), it also allows users to 
define customized feature clustering methods in order to increase its compatibility regardless 
of the way of representing or encoding the information.  
 
Then, for each split of the original dataset, D2-MCS is able to detect the most effective 
classifier (and its best configuration) from a wide variety of ML techniques (up to 236 
different classifiers from 47 families [36]). The best classifiers for each knowledge partition 
together with their optimal configurations are compiled together to act as a set of individual 
experts whose outputs should be combined to generate a final result. To this end, D2-MCS 
implements two simple methods to combine the outputs of inner classifiers (see SOLUTION 
CALCULATOR part in Figure 1) and it provides an API to easily define new output 
aggregator methods [21]. 
Then, the third stage (see SOLUTION CALCULATOR part in Figure 1) is responsible for 
compiling the best classifier for each cluster (achieving highest performance values) together 
with their optimal configuration to act as a set of individual experts whose outputs should be 
combined to generate a final solution. To this end, D2-MCS implements two simple methods 
to combine the outputs of inner classifiers (one inner classifier per cluster): (i) a simple 
majority voting system where the final class is the one obtaining more than half of the votes 
and (ii) a weighted majority voting where the winner is the class achieving the highest overall 
value.  
 
In order to execute our experimentation, the dataset instances (rows) were randomly divided 
into four homogeneous and evenly sized groups. Figure 2 represents the configuration of 
groups and their usage for evaluating MCSs and single ML techniques. 
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Figure 2. Dataset partitioning. The dataset instances (rows) were randomly divided into four 
homogeneous and evenly sized groups. 
As shown in Figure 2, the first two groups were used to select an appropriate number of 
feature-clusters for MCS systems. Then, the second and third groups were used to build the 
MCS (select the most appropriate classifier for each dataset partition, build classifiers, and 
optimize their configurations). Finally, the fourth group has been reserved to assess the 
performance of the achieved MCS.  
As previously stated, during the first stage of D2-MCS process (see Figure 1) the original 
dataset is divided into several groups of non-repeated features. Although the latest version 
D2-MCS provides several feature-clustering algorithms, we used the same clustering 
method as used in [21] (called MultiTypeFisherClustering) due to the good results achieved 
in this domain. Concretely, the experimentation carried out in [21] demonstrated the 
suitability of dividing the features into three clusters. 
Once the best clustering configuration is obtained (three clusters), the MCS building stage is 
executed. In detail, this stage is responsible for determining the best ML models (and 
parameter configuration) for each cluster. Additionally, D2-MCS allows defining an objective 
function to customize the model parameter-optimization process. To follow the same 
criterion as previously commented, we use both PPV and MCC measures, which entails the 
generation of two different MCCs (PPV-based and MCC-based models). 
Then, in order to test the final performance, both MCS (PPV-based and MCC-based) were 
executed over the remaining dataset (see Group 4 in Figure 2) composed by 982 instances 
(504 active and 478 inactive compounds). To compute the final class of each compound, the 
outputs of the inner classifiers included in each MCS are combined using a voting scheme 
where a compound is classified as Active whenever the number of positive outputs of each 
inner classifiers is greater or equal than the negative ones. Conversely, the compound is 
classified as Inactive. 
To follow the evaluation criteria used during the optimization stage, the classification 
performance achieved for each experimental configuration was assessed using both MCC 
and PPV measures (see Figure 3). Additionally, Figure 3 represents (i) the final performance 
achieved for each measure and (ii) the confusion matrix values (TP, TN, FP and FN). For 
comparison purposes, Figure 3 also includes the performance achieved on each cluster 
during the training stage.  
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 Figure 3. Performance comparison plot for the testing stage. A) indicates the performance 
obtained using the MCC measure and B) shows the performance obtained using the PPV 
measure. 
 
As can be realised from Figure 3A, the performance achieved during the test stage slightly 
outperforms the individual outcomes obtained during the optimization stage. Additionally, the 
use of the MCC measure allows achieving a balanced number of misclassification errors 
(FP≈FN). Furthermore, from Figure 3B it is easy to realise that using PPV as an objective 
function significantly reduces the number of FP errors at expenses of increasing FN errors. 
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Additionally, after performing a global overview of Figure 3 we can realise: (i) the ability to 
build a suitable measure-guided knowledge-generalization models, and (ii) the importance of 
using an adequate domain-oriented measure in order to minimize the number of 
misclassification errors. In fact, as can be seen in Figure 3, MCC based models achieve 
fewer error rates than the PPV measure (113 and 132 errors respectively). Despite this, the 
results are quite promising (the rate of correctly classified compounds is very high), although 
we are aware that can be increased even more by taking advantage of the intrinsic 
characteristics of MCS. 
In order to demonstrate this hypothesis, we generate two meta-models by combining the 
predictions achieved by the MCS models trained using MCC and PPV measures (see 
Minimize FP and Minimize FN in Figure 4). Concretely, Minimize FP is responsible for 
labelling the target compound as Active whenever is predicted as ‘Active’ by both MCS (PPV 
and MCC) while Minimize FN identifies the target compound as Active only if one of the 
MCS (PPV and MCC) predicts the compound as ‘Active’. For comparison purposes, both 
meta-models were executed over the same testing dataset (see Group 4 in Figure 2) as 
used by primitive MCS models (PPV-based and MCC-based). 
 
Figure 4. Performance comparison achieved for Minimize FP and Minimize FN meta-models. 
As can be seen in Figure 4, both meta-models clearly improve the performance achieved by 
the primitive MCS models. Focusing on the first approximation (Minimize FP), the 
performance is increased up to 6.45% (MCC) and 7.32% (PPV) regarding the original 
models optimised for MCC and PPV respectively. On the other hand, the second meta-
model outperforms up to 11.91% (MCC) and 7.85% (PPV) the results achieved with regards 
the corresponding primitive models. Although the second approximation seems the most 
suitable alternative (best values of MCC and PPV), the Accuracy measure points Minimize 
FP as the best model. The main reason for this circumstance can be easily explained 
through the confusion matrix described in Table 2. 
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As can be seen in Table 2, the number of overall errors achieved by second approximation 
is bigger than Minimize FP (84 vs 33 respectively). Taking into account that Accuracy 
computes the overall probability of performing a correct classification, it is easy to conclude 
that the low rate of misclassification errors motivates the good Accuracy level achieved by 
first approximation. 
Table 2. Confusion matrix achieved for both configurations. 
 TP FP TN FN 
MINIMIZE FP 474 3 475 30 
MINIMIZE FN 480 60 418 24 
Additionally, as can be realised from Table 2, the ability to avoid discarding potential Active 
compounds makes Minimize FN an adequate alternative for the research domain (where 
discovering the whole spectrum of potential candidate drugs is more important than 
minimizing trial costs). Conversely, Minimize FP approximation achieves a significant 
reduction of FP errors (up to 95%) when compared with Minimize FP. This fact makes 
Minimize FP a suitable approximation for the pharmaceutical industry where minimizing 
unnecessary trial tests (reduce costs) is more important than losing potential Active 
candidates.  
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Probabilistic-based ranking methodology 
The designed probabilistic-based methodology was used to rank active-predicted 
compounds from the ValidationSet. As can be seen in Figure 5, the first stage is responsible 
for compiling from all inner individual classifiers included Minimize FP model (an MCS model 
comprising 3 classifiers for optimizing PPV and another one with 3 inner models for MCC) 
the class probability of each compound tagged as Active (48,232). As can be depicted from 
stage 1 in Figure 5, the achieved probabilities are always greater than 0.5 since only 
compounds previously labelled as Active (Active > 0.5, Inactive <= 0.5) were selected.  
 
Figure 5. Workflow of three-stage potential candidate ranker methodology. Our ranking 
methodology comprised three main stages: (i) class probability estimator, (ii) global 
relevance calculator and (iii) relevance sorter. 
Once all probabilities are obtained, during the second stage we compute the global 
relevance (denoted as   in Figure 5) of each candidate as a mathematical product of all its 
probabilities (see Equation 3). 
1
numcluster
i
i
C

     3 
where numcluster stands form the number of clusters comprising the used meta-model. 
Combining these probabilities using the product operator allows achieving a wide variety of 
output values (and thereby improves compatibility) even when individual input values are 
very close. As an example, given two vectors of values [0.75, 0.75, 0.6], [0.6, 0.9, 0.6], the 
product operator ( ) is able to achieve 0.337 and 0.324 respectively, while the summation 
( ) and the arithmetic mean ( ) obtain the same values for both vectors (2.1 and 0.7 
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respectively). Finally, the third stage entails the arrangement of the chemical compounds by 
descendant according to its global relevance value ( ). This ensures that the best 
candidates are placed in the initial positions. 
Chemical clustering 
The 48,232 predicted actives were clustered based on the same binary features (FCFP_6) 
that were used for model training using the cluster molecules component in Pipeline Pilot 
version 2016 [24]. An average cluster population of 20 was selected and the maximum 
Tanimoto distance between the cluster centre and members was set at 0.35 (forcing a 
similarity of > 0.65 within clusters), resulting in 28,217 clusters. 
In Vitro Experimental Techniques 
Cell culture and membrane preparation 
CHOK1hCB2_bgal cells (DiscoverRx, Fremont, CA, USA) were cultured in Dulbecco’s 
Modified Eagle’s Medium/Nutrient Mixture F-12 Ham supplemented with 10% fetal calf 
serum, 1 mM glutamine, 50 µg/mL penicillin, 50 µg/mL streptomycin, 300 mg/mL hygromycin 
and 800 µg/mL geneticin in a humidified atmosphere at 37°C and 5% CO2. Cells were 
subcultured twice a week at a ratio of 1:20 on 10-cm diameter plates by trypsinization. For 
membrane preparation, the cells were subcultured with a ratio of 1:10 and transferred to 15-
cm diameter plates. The cells were collected by scraping in 5 mL phosphate-buffered saline 
(PBS) and centrifuged at 1,000g for 5 min. Pellets derived from 30 plates were combined 
and resuspended in 20 mL cold Tris-HCl, MgCl2 buffer (50 mM Tris-HCl (pH 7.4), 5 mM 
MgCl2). The cell suspension was homogenized using an UltraTurrax homogenizer (Heidolph 
Instruments Schwabach, Germany). Membranes and cytosolic fractions were separated by 
centrifugation in a Beckman Optima LE-80K ultracentrifuge (Beckman Coulter Inc., Fullerton, 
CA, USA) at 100,000 g for 20 min at 4°C. The supernatant was discarded. The pellet was 
resuspended in 10 mL cold Tris-HCl, MgCl2 buffer and homogenization and centrifugation 
steps were repeated. The membranes were resuspended in 10 mL cold Tris-HCl, MgCl2 
buffer. Aliquots of 50 µL were stored at -80°C until further use. The protein concentration 
was determined using the Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific, 
Waltham, MA, USA). 
[
3
H]CP55940 Displacement assay 
[3H]CP55940 displacement assays on 96-well plates were performed in 50 mM Tris-HCl (pH 
7.4), 5 mM MgCl2, and 0.1% BSA assay buffer. Membrane aliquots of CHOK1CB2_bgal 
containing 1.5 µg membrane protein were incubated at 25°C for 2h in the presence of ~1.5 
nM [3H]CP55940 (specific activity 149 Ci/mmol; PerkinElmer, Waltham, MA). At first, all 
compounds were tested at a final concentration of 10 µM. When radioligand displacement 
was greater than 50%, full curves were recorded to determine the affinity (pKi) values of the 
compounds. Six different concentrations of the compounds were added by an HP D300 
digital dispenser (Tecan Group Ltd, Männedorf, Switzerland). In order to determine the total 
binding, a control without test compound was included. Nonspecific binding was determined 
in the presence of 10 µM AM630. The total assay volume was 100 µL. The final 
concentration of DMSO was ≤ 0.25%. The incubation was terminated by rapid vacuum 
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filtration through GF/C 96-well filter plates (PerkinElmer, Waltham, MA), to separate the 
bound and free radioligand, using a PerkinElmer Filtermate-harvester (PerkinElmer, 
Groningen, The Netherlands). Filters were subsequently washed twenty times with ice-cold 
assay buffer. The filter-bound radioactivity was determined by scintillation spectrometry 
using a Microbeta2® 2450 microplate counter (PerkinElmer, Boston, MA), after addition of 
25μl MicroScint 20 (PerkinElmer, Groningen, The Netherlands) and 3h incubation. 
Data Analysis 
All experimental data were analyzed using GraphPad Prism 7 [37]. The data were 
normalized to percentage specific radioligand binding, where the total binding is 100% and 
nonspecific binding is 0%. Nonlinear regression for one-site was used to determine the IC50 
values from the full curve [3H]CP55940 displacement assays. The pKi values were obtained 
using Equation 4 proposed by Cheng-Prusoff [38]. 
 
50
1
i
D
IC
K
L
K

  
   
  
 
4 
where [L] is the exact concentration [3H]CP55940 determined per experiment and the KD is 
the dissociation constant of [3H]CP55940, which is 1.24 nM as determined by Soethoudt et 
al [38]. All data were obtained from three separate experiments performed in duplicate. 
Results 
This section presents the effectiveness achieved by our proposal. To this end, we get the 
potential candidates by applying our MCS models over the Validation set. Moreover, most 
promising candidates were used by executing our probabilistic-based ranking methodology. 
Finally, in vitro analysis were performed over the previously achieved candidates to 
determine their real activity. 
Virtual Screening 
We applied our MCS models in virtual screening in a non-controlled environment. Here, we 
do not know the activities of the chemical compounds. Virtual screening refers to the use of 
computational approaches to identify chemical structures that are predicted to have 
particular properties. To this end, we designed new experimentation to analyse the 
behaviour of both meta-models (Minimize FP and Minimize FN) in a realistic scenario. We 
classified a list of chemical compounds included in the ValidationSet in order to determine 
their activity. Below, Table 4 summarizes the outcomes achieved by each model grouped by 
activity (Active or Inactive). As can be depicted for Table 4, the number of Active compounds 
predicted by Minimize FN is higher than Minimize FP (representing 9.085% and 2.629% of 
the whole dataset), while Minimize FP was able to classify more compounds as Inactive.  
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Table 3: Summary of predictions group by model. 
Meta-models 
Predictions 
Minimize FP Minimize FN 
48,232 166,664 Active 
1,786,130 1,667,698 Inactive 
1,834,362 1,834,362 Total 
This scenario clearly fits the behaviour described in Table 3, where Minimize FP trends to 
reduce the FP rate despite sacrificing potential Active compounds while Minimize FN is 
focused on exploring all the potential candidate compounds at expenses of increasing the 
number of unnecessary trials (caused by FP errors).  
The high amount of potential Active components (48,232) makes it infeasible (in terms of 
human resources and trial cost) to perform an evaluation of all the predicted actives. 
Therefore, we selected candidates for experimental validation from the compounds classified 
as Active by Minimize FP. We address the importance of using an adequate candidate-
selection method when dealing with a reduced set of compounds (representing only 0.083% 
of the potential candidates) to avoid obtaining unrepresentative information. To prevent 
random selection of candidates, we combined a chemical clustering method with a 
probabilistic-based ranking methodology. The designed probabilistic-based ranking 
methodology was used to rank each active-predicted compound (see Additional File 2). This 
ranking was subsequently used to select the most suitable candidates from chemical 
clusters. These clusters were constituted from the list of 48,232 predicted actives. Clustering 
of the predicted actives resulted in 28,217 chemical clusters. From each cluster, the top 
scoring member (based on the ranks generated by the probabilistic-based ranking 
methodology) was kept while the other cluster members were discarded. Finally, the top 60 
scoring compounds (60 clusters) were selected and 21 novel and diverse compounds were 
purchased. The average similarity in the set based on Tanimoto similarity was 0.19 ± 0.11, 
the average probability to be active was 0.77 ± 0.02, and the average similarity to the 
training set was 0.74 ± 0.06 (distance 0.26). Hence, it can be concluded that the set selected 
wash internally chemically diverse, highly probable to be active, and relatively close to the 
training set. 
In Vitro Evaluation 
The affinities of the 21 purchased compounds for the human CB2 receptor were determined 
in a radioligand displacement assay using [3H]CP55940 as the radiolabeled competitor 
(Table 4). Six compounds were able to displace more than 50% of the radioligand at 10 uM, 
and were thus further characterized for their affinity, where the compound with the highest 
affinity was Z336532434 (pKi 7.67). Taken together, we were able to obtain 11 hits from the 
21 novel compounds (representing a 52% hit rate). As can be seen from Table 4, four out of 
these 11 are in the top five based on probability. Moreover, the top 10 compounds based on 
probability contained 7 out of 11 actives. We conclude that our defined probability can be a 
good estimator of biological activity. Most notable is compound Z27680708, which was 
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measured to have a pKi of 7.46 while the Tanimoto similarity to the training set was the 
lowest of the 21 tested compounds at 0.69.  
Table 4: Experimentally validated compounds 
Data Image 
IDnumber  
/  
InChiKey 
Probability 
Distance 
To 
Closest 
pKi ±SEM 
or  
% displ. 
 
Z336532434 
/ 
MQIUMQLPFGFWME-UHFFFAOYSA-N 
0.82 0.32 7.67 ±0.17 
 
Z28609248 
/ 
HXJYJTXXUOYRSB-UHFFFAOYSA-N 
0.81 0.29 16% 
 
Z26476746 
/ 
VYCWCTZNPBMJFW-UHFFFAOYSA-N 
0.80 0.21 6.54 ±0.14 
 
Z91179667 
/ 
XGVYRTRSINEVTE-UHFFFAOYSA-N 
0.78 0.15 29% 
 
 
Z32934509 
/ 
OLTBRCMQFCQBIR-UHFFFAOYSA-N 
0.78 0.28 6.47 ±0.02 
 
Z28357657 
/ 
NPRYSOPFJOGFSA-UHFFFAOYSA-N 
0.78 0.34 6.81 ±0.29 
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 Z30007452 
/ 
VBFKBSAAMKINJD-UHFFFAOYSA-N 
0.77 0.24 -2% 
 
Z27687312 
/ 
IHBHBQAPEZJCNM-UHFFFAOYSA-N 
0.77 0.23 7.22 ±0.46 
 
Z46091805 
/ 
QKQCBVJKUBSZOR-UHFFFAOYSA-N 
0.76 0.24 38% 
 
Z27687279 
/ 
WTGACPGXOMAZFA-UHFFFAOYSA-N 
0.76 0.22 38% 
 
Z44866691 
/ 
WPWBUEOMELTWOC-FCDQGJHFSA-N 
0.76 0.25 -1% 
 
Z28357392 
/ 
VBIMVPWQQQESTK-UHFFFAOYSA-N 
0.76 0.13 26% 
 
Z1317886912 
/ 
MEXULSRPIBCDQX-UHFFFAOYSA-N 
0.76 0.28 3% 
 
Z44867007 
/ 
PCCXRCZRXNECAZ-JLPGSUDCSA-N 
0.76 0.30 0% 
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 Z237484560 
/ 
LIGIHTRZFDFDAN-UHFFFAOYSA-N 
0.75 0.15 -1% 
 
Z223843850 
/ 
CVSSLUCDGJDGHX-UHFFFAOYSA-N 
0.75 0.32 -5% 
 
Z27019562 
/ 
WNXCAGCQOBOQMO-UHFFFAOYSA-N 
0.75 0.33 30% 
 
Z55473655 
/ 
VDTRQSFAESBVFB-UHFFFAOYSA-N 
0.75 0.26 7% 
 
Z2094674960 
/ 
RISCNDGLDMULEE-UHFFFAOYSA-N 
0.75 0.29 0% 
 
Z1523102560 
/ 
IXASXIGZGJSBJT-UHFFFAOYSA-N 
0.75 0.30 18% 
 
Z27680708 
/ 
HKWXDCJIBMAAFV-UHFFFAOYSA-N 
0.74 0.31 7.46 ±0.32 
Shown are the structure, enamine identifier (ID number), InChIKey, assigned probability, 
distance to the training set, and biological activity. Biological activity is shown as pKi (with a 
standard error of the mean) when available or % displacement of the radioligand by 10 uM of 
the compound. Identified novel hits are indicated in bold.  
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Conclusions 
This work uses Multiple Classifier Systems (MCS) applied in early preclinical drug discovery.  
Concretely, we apply D2-MCS over a training dataset to build two measure-guided MCS 
(PPV and MCC). Furthermore, two meta-models (Minimize FP and Minimize FN) were 
generated by combining the predictions achieved by the previous MCS models.  
Results achieved by both meta-models show the suitability of using Minimize FP due to its 
ability to avoid FP errors (only 3 from 477). To this end, we execute Minimize FP over a 
validation dataset (comprised of 1.834.362 compounds) together with our probabilistic-based 
ranking methodology to obtain the 21 most promising active compounds. 
We have demonstrated that an appropriate combination of MCS can be successfully used 
for virtual screening (to predict the biological activity of chemical structures). The identified 
hits were chemically diverse while similar to the training set. We were successfully able to 
determine a probability of biological activity, which demonstrated a predictive performance 
for biological activity.  
Despite the promising results achieved here (being 52.38% hits), further improvements 
should be addressed to increase the classification performance. Therefore, future work 
should be focused on two main aspects (i) dataset processing and (ii) the improvement of 
D2-MCS toolkit. Regarding data quality, the detection, and removal of irrelevant, noisy, or 
valueless features from the input dataset should be considered. Moreover, to increase the 
performance of D2-MCS new and efficient feature clustering methods should be 
implemented.  
Additional files 
Additional File 1. Physicochemical descriptors comprising CB2Set.  
Additional File 2. List of potential candidates sorted by probability of being Active. 
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